ESC 365 - Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment

ESC Premium Access

Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment

Session: Advances in the Management of Pulmonary Arterial Hypertension

Topic: Pulmonary Hypertension

Speaker: Associate Professor R. Badagliacca (Rome, IT)

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Associate Professor Roberto Badagliacca

Sapienza University of Rome, Rome (Italy)

1 presentation

0 follower

2 more presentations in this session

Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)

Speaker: Doctor V. McLaughlin (Ann Arbor, US)

Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil

Speaker: Doctor R. Sadushi-Kolici (Vienna, AT)

Access the full session

Advances in the Management of Pulmonary Arterial Hypertension

Speakers: Associate Professor R. Badagliacca, Doctor V. McLaughlin, Doctor R. Sadushi-Kolici

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources